RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $328
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Amgen (NASDAQ:AMGN) but lowered the price target from $332 to $328.

May 03, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains Outperform on Amgen with a reduced price target from $332 to $328.
The adjustment in price target by RBC Capital, while still maintaining an Outperform rating, suggests a slight recalibration of expectations rather than a fundamental shift in the company's outlook. The reduction is relatively minor, indicating that the analyst's view on the company's performance potential remains largely positive. However, the change might lead to short-term trading volatility as investors adjust to the new target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100